DBV Technologies (DBVT) Cash & Equivalents (2015 - 2026)
DBV Technologies (DBVT) posted Cash & Equivalents of $174.9 million for Q2 2026, down 23.69% sequentially from $229.2 million in Q1 2026, and up 69.47% YoY from $103.2 million in Q2 2025.
DBV Technologies (DBVT) Cash & Equivalents (2015 - 2026) Analysis & Trends
DBV Technologies has reported Cash & Equivalents for 12 years, with the latest figure at $174.9 million in Q2 2026.
- Quarterly Cash & Equivalents rose 69.47% year-over-year to $174.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $174.9 million (up 69.47% YoY) and the FY2025 annual result came in at $194.2 million, up 498.35% from the prior year.
- Cash & Equivalents slipped to $174.9 million in Q2 2026 per DBVT's latest filing, from $229.2 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $248.0 million in Q2 2022 and troughed at $13.0 million in Q1 2025.
- A 5-year average of $135.1 million and a median of $145.3 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2025 and 2026: Cash & Equivalents sank 87.23% in 2025, then soared 1668.25% in 2026.
- Over 5 years, Cash & Equivalents stood at $209.2 million in 2022, then plunged by 32.42% to $141.4 million in 2023, then sank by 77.04% to $32.5 million in 2024, then surged by 498.35% to $194.2 million in 2025, then dropped by 9.94% to $174.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $174.9 million, $229.2 million, and $194.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 174.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 174.90 Mn |
| Mar 31, 2026 | 229.20 Mn |
| Dec 31, 2025 | 194.20 Mn |
| Sep 30, 2025 | 69.84 Mn |
| Jun 30, 2025 | 103.21 Mn |
| Mar 31, 2025 | 12.96 Mn |
| Dec 31, 2024 | 32.46 Mn |
| Sep 30, 2024 | 46.44 Mn |
| Jun 30, 2024 | 66.21 Mn |
| Mar 31, 2024 | 101.53 Mn |
| Dec 31, 2023 | 141.37 Mn |
| Sep 30, 2023 | 149.14 Mn |
| Jun 30, 2023 | 173.96 Mn |
| Mar 31, 2023 | 192.29 Mn |
| Dec 31, 2022 | 209.19 Mn |
| Sep 30, 2022 | 212.67 Mn |
| Jun 30, 2022 | 247.97 Mn |
| Mar 31, 2022 | 74.11 Mn |
| Dec 31, 2021 | 77.30 Mn |
| Sep 30, 2021 | 98.20 Mn |